ORLOWSKI, RZ., A. NAGLER, P. SONNEVELD, J. BLADÉ and Roman HÁJEK. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of clinical oncology. United States: American Society of Clinical Oncology, 2007, vol. 25, No 25, p. 3892-3901. ISSN 0732-183X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Name in Czech Randomizovaná studie fáze II porovnání kombinované léčby doxorubicin/bortezomib se samotným bortezomibem
Authors ORLOWSKI, RZ. (840 United States of America), A. NAGLER (840 United States of America), P. SONNEVELD (840 United States of America), J. BLADÉ (840 United States of America) and Roman HÁJEK (203 Czech Republic, guarantor).
Edition Journal of clinical oncology, United States, American Society of Clinical Oncology, 2007, 0732-183X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 15.484
RIV identification code RIV/00216224:14110/07:00035887
Organization unit Faculty of Medicine
UT WoS 000249416000018
Keywords (in Czech) mnohočetný myelom;bortezomib;doxorubicin
Keywords in English multiple myeloma; bortezomib;doxorubicin
Tags bortezomib, doxorubicin, multiple myeloma
Tags International impact
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 22/6/2009 17:58.
Abstract
This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. PLD with bortezomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma. The combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities.
Abstract (in Czech)
V publikaci jsou posány výsledky III fáze mezinárodní studie, ve které byly porovnávány účinky samotného bortezomibu a kombinované léčby s doxorubicinem.
PrintDisplayed: 2/5/2024 18:19